Skip to main content

Advertisement

SpringerLink
Log in

Changing the Perspective on Fertility Preservation for Women with Metastatic or Advanced Stage Cancer

  • REVIEW
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

In this Perspective we share the personal story of a 33-year-old patient diagnosed with metastatic breast cancer and her journey through fertility preservation, surrogacy, and eventually motherhood, highlighting misconceptions about fertility preservation in this population.

Recent Findings

There are nearly 1 million women under the age of 50 diagnosed and living with cancer in the USA. These patients are met with life-altering decisions, including those that may limit their reproductive ability. While there have been tremendous advances and advocacy in the field of oncofertility, there has been limited focus on patients with advanced stage or metastatic cancer.

Summary

We describe five key misconceptions surrounding fertility preservation in patients with advanced stage cancer, offering a review of the literature and our approach to challenging topics like desiring fertility preservation in the face of Stage 4 disease, the safety and timing of ovarian stimulation during cancer treatment, and passing away following fertility preservation. We review the importance of assessing perceptions of fertility preservation in patients with metastatic cancer and highlight the lack of research in this area as a call to action.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. American Cancer Society. American Cancer Society. Cancer facts & figures 2022. Atlanta: American Cancer Society; 2022.

  2. Epstein RJ. Drug-induced DNA damage and tumor chemosensitivity. J Clin Oncol. 1990;8(12):2062–84. https://doi.org/10.1200/JCO.1990.8.12.2062.

    Article  CAS  PubMed  Google Scholar 

  3. Meirow D, Biederman H, Anderson RA, Wallace WHB. Toxicity of chemotherapy and radiation on female reproduction. Clin Obstet Gynecol. 2010;53(4):727–39. https://doi.org/10.1097/GRF.0B013E3181F96B54.

    Article  PubMed  Google Scholar 

  4. Meirow D, Dor J, Kaufman B, et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod. 2007;22(6):1626–33. https://doi.org/10.1093/HUMREP/DEM027.

    Article  CAS  PubMed  Google Scholar 

  5. Brämswig JH, Riepenhausen M, Schellong G. Parenthood in adult female survivors treated for Hodgkin’s lymphoma during childhood and adolescence: a prospective, longitudinal study. Lancet Oncol. 2015;16(6):667–75. https://doi.org/10.1016/S1470-2045(15)70140-3.

    Article  PubMed  Google Scholar 

  6. Anderson RA, Wallace WHB. Pregnancy and live birth after successful cancer treatment in young women: the need to improve fertility preservation and advice for female cancer patients. Expert Rev Anticancer Ther. 2018;18(1):1–2. https://doi.org/10.1080/14737140.2018.1404453.

    Article  CAS  PubMed  Google Scholar 

  7. Letourneau JM, Melisko ME, Cedars MI, Rosen MP. A changing perspective: improving access to fertility preservation. Nat Rev Clin Oncol. 2011;8(1):56–60. https://doi.org/10.1038/NRCLINONC.2010.133.

    Article  PubMed  Google Scholar 

  8. Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001. https://doi.org/10.1200/JCO.2018.78.1914.

    Article  PubMed  Google Scholar 

  9. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2019;112(6):1022–1033. https://doi.org/10.1016/J.FERTNSTERT.2019.09.013

  10. Catania C, del Signore E, Spitaleri G. The desire for life and motherhood despite metastatic lung cancer. JAMA Oncol. 2019;5(11):1537–8. https://doi.org/10.1001/JAMAONCOL.2019.2588.

    Article  PubMed  Google Scholar 

  11. Quinn GP, Vadaparampil ST, Lee JH, et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol. 2009;27(35):5952–7. https://doi.org/10.1200/JCO.2009.23.0250.

    Article  PubMed  Google Scholar 

  12. Tschudin S, Bitzer J. Psychological aspects of fertility preservation in men and women affected by cancer and other life-threatening diseases. Hum Reprod Update. 2009;15(5):587–97. https://doi.org/10.1093/HUMUPD/DMP015.

    Article  PubMed  Google Scholar 

  13. Awtani M, Mathur K, Shah S, Banker M. Infertility stress in couples undergoing intrauterine insemination and in vitro fertilization treatments. J Hum Reprod Sci. 2017;10(3):221–5. https://doi.org/10.4103/JHRS.JHRS_39_17.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Slomski A. Fertility preservation after breast cancer diagnosis. JAMA. 2022;328(13):1289. https://doi.org/10.1001/JAMA.2022.15441.

    Article  PubMed  Google Scholar 

  15. Quintero RB, Helmer A, Huang JQ, Westphal LM. Ovarian stimulation for fertility preservation in patients with cancer. Fertil Steril. 2010;93(3):865–8. https://doi.org/10.1016/J.FERTNSTERT.2008.10.007.

    Article  CAS  PubMed  Google Scholar 

  16. Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril. 2013;99(6):1476–84. https://doi.org/10.1016/J.FERTNSTERT.2013.03.029.

    Article  PubMed  Google Scholar 

  17. Reddy J, Turan V, Bedoschi G, Moy F, Oktay K. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience. J Assist Reprod Genet. 2014;31(7):927–32. https://doi.org/10.1007/S10815-014-0248-6.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Christ J, Herndon CN, Yu B. Severe ovarian hyperstimulation syndrome associated with long-acting GnRH agonist in oncofertility patients. J Assist Reprod Genet. 2021;38(3):751–6. https://doi.org/10.1007/S10815-020-02051-7.

    Article  PubMed  PubMed Central  Google Scholar 

  19. • Wald K, Letourneau J, Eshima-McKay R, et al. Ovarian stimulation and egg retrieval in the acutely ill patient: special considerations. J Assist Reprod Genet. 2019;36(10):2087–94. https://doi.org/10.1007/S10815-019-01556-0. This review describes the methods and considerations of ovarian stimulation and egg retrieval in individuals who have a severe medical condition.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Albert C, Garrido N, Mercader A, et al. The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome. Mol Hum Reprod. 2002;8(5):409–18. https://doi.org/10.1093/MOLEHR/8.5.409.

    Article  CAS  PubMed  Google Scholar 

  21. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis. 2008;11(2):109–19. https://doi.org/10.1007/S10456-008-9099-Z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Agrawal R, Tan SL, Wild S, et al. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril. 1999;71(2):287–93. https://doi.org/10.1016/S0015-0282(98)00447-6.

    Article  CAS  PubMed  Google Scholar 

  23. Morita T, Tei Y, Inoue S, Suga A, Chihara S. Fluid status of terminally ill cancer patients with intestinal obstruction: an exploratory observational study. Support Care Cancer. 2002;10(6):474–9. https://doi.org/10.1007/S00520-002-0358-Z.

    Article  PubMed  Google Scholar 

  24. Amano K, Liu D, Bruera E, Hui D. Collapse of fluid balance and association with survival in patients with advanced cancer admitted to a palliative care unit: preliminary findings. J Palliat Med. 2020;23(4):459–65. https://doi.org/10.1089/JPM.2019.0392.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Bassiouny YA, Dakhly DMR, Bayoumi YA, Salaheldin NM, Gouda HM, Hassan AA. Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. Int J Gynaecol Obstet. 2018;140(2):217–22. https://doi.org/10.1002/IJGO.12360.

    Article  CAS  PubMed  Google Scholar 

  26. Carizza C, Abdelmassih V, Abdelmassih S, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online. 2008;17(6):751–5. https://doi.org/10.1016/S1472-6483(10)60401-4.

    Article  CAS  PubMed  Google Scholar 

  27. Kilic N, Özdemir Ö, Başar HC, Demircan F, Ekmez F, Yücel O. Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: a randomized controlled study. Avicenna J Med. 2015;5(4):123–7. https://doi.org/10.4103/2231-0770.165121.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Tang H, Hunter T, Hu Y, Zhai SD, Sheng X, Hart RJ. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2012;(2). https://doi.org/10.1002/14651858.CD008605.PUB2

  29. Bates SM. Anticoagulation and in vitro fertilization and ovarian stimulation. Hematology Am Soc Hematol Educ Program. 2014;2014(1):379–86. https://doi.org/10.1182/ASHEDUCATION-2014.1.379.

    Article  PubMed  Google Scholar 

  30. Kondapalli LA, Hong F, Gracia CR. Clinical cases in oncofertility. Cancer Treat Res. 2010;156:55–67. https://doi.org/10.1007/978-1-4419-6518-9_5.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Azim A, Oktay K. Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma. Fertil Steril. 2007;88(3):657–64. https://doi.org/10.1016/J.FERTNSTERT.2006.12.068.

    Article  CAS  PubMed  Google Scholar 

  32. Letourneau J, Juarez-Hernandez F, Wald K, et al. Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial. J Assist Reprod Genet. 2021;38(9):2455–63. https://doi.org/10.1007/S10815-021-02273-3.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Pereira N, Hancock K, Cordeiro CN, Lekovich JP, Schattman GL, Rosenwaks Z. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†. Gynecol Endocrinol. 2016;32(10):823–6. https://doi.org/10.1080/09513590.2016.1177013.

    Article  CAS  PubMed  Google Scholar 

  34. Ferreiro E, de Uralde BL, Abreu R, García-Velasco JA, Muñoz E. Aromatase inhibitors for ovarian stimulation in patients with breast cancer. Curr Drug Targets. 2020;21(9):910–21. https://doi.org/10.2174/1389450121666200220124607.

    Article  CAS  PubMed  Google Scholar 

  35. Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol. 2005;23(16):3858–9. https://doi.org/10.1200/JCO.2005.04.011.

    Article  PubMed  Google Scholar 

  36. Muñoz E, Domingo J, de Castro G, et al. Ovarian stimulation for oocyte vitrification does not modify disease-free survival and overall survival rates in patients with early breast cancer. Reprod Biomed Online. 2019;39(5):860–7. https://doi.org/10.1016/J.RBMO.2019.07.003.

    Article  PubMed  Google Scholar 

  37. Turan V, Bedoschi G, Moy F, Oktay K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril. 2013;100(6). https://doi.org/10.1016/J.FERTNSTERT.2013.08.030

  38. Rodgers RJ, Reid GD, Koch J, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod. 2017;32(5):1033–45. https://doi.org/10.1093/HUMREP/DEX027.

    Article  CAS  PubMed  Google Scholar 

  39. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347–53. https://doi.org/10.1200/JCO.2005.05.037.

    Article  CAS  PubMed  Google Scholar 

  40. Moravek MB, Confino R, Lawson AK, et al. Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation. Breast Cancer Res Treat. 2021;186(2):429–37. https://doi.org/10.1007/S10549-020-06031-4.

    Article  CAS  PubMed  Google Scholar 

  41. Marklund A, Eloranta S, Wikander I, et al. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study. Hum Reprod. 2020;35(4):929–38. https://doi.org/10.1093/HUMREP/DEAA029.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Luke B, Brown MB, Missmer SA, et al. Assisted reproductive technology use and outcomes among women with a history of cancer. Hum Reprod. 2016;31(1):183–9. https://doi.org/10.1093/HUMREP/DEV288.

    Article  PubMed  Google Scholar 

  43. •• Letourneau JM, Wald K, Sinha N, et al. Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation. Cancer. 2020;126(3):487–95. https://doi.org/10.1002/CNCR.32546. This study of 329 patients with invasive breast cancer showed no impact of fertility preservation on disease-free survival, including for those with estrogen receptor-positive disease or those treated with neoadjuvant chemotherapy.

    Article  PubMed  Google Scholar 

  44. Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab. 2016;101(4):1364–71. https://doi.org/10.1210/JC.2015-3878.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Goldrat O, Kroman N, Peccatori FA, et al. Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. Eur J Cancer. 2015;51(12):1490–6. https://doi.org/10.1016/J.EJCA.2015.05.007.

    Article  PubMed  Google Scholar 

  46. Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R. Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril. 2012;97(1):125–33. https://doi.org/10.1016/J.FERTNSTERT.2011.10.014.

    Article  PubMed  Google Scholar 

  47. Chien AJ, Chambers J, Mcauley F, et al. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017;165(1):151–9. https://doi.org/10.1007/S10549-017-4288-3.

    Article  PubMed  Google Scholar 

  48. •• Marklund A, Lekberg T, Hedayati E, et al. Relapse rates and disease-specific mortality following procedures for fertility preservation at time of breast cancer diagnosis. JAMA Oncol. 2022;8(10):1438–46. https://doi.org/10.1001/JAMAONCOL.2022.3677. A nationwide cohort study of women with breast cancer who underwent fertility preservation found that fertility preservation at the time of breast cancer diagnosis was not associated with increased disease-specific mortality or relapse.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26(16):2630–5. https://doi.org/10.1200/JCO.2007.14.8700.

    Article  CAS  PubMed  Google Scholar 

  50. Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Smith KL, Ferreiro T, Ribi K, Ruddy K, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, International Breast Cancer Study Group, POSITIVE trial collaborators. POSITIVE trial collaborators interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023;388(18):1645–56. https://doi.org/10.1056/nejmoa2212856.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100(6):1673–80. https://doi.org/10.1016/J.FERTNSTERT.2013.07.1992.

    Article  PubMed  Google Scholar 

  52. Cakmak H, Rosen MP. Random-start ovarian stimulation in patients with cancer. Curr Opin Obstet Gynecol. 2015;27(3):215–21. https://doi.org/10.1097/GCO.0000000000000180.

    Article  PubMed  Google Scholar 

  53. Hudson JN, Stanley NB, Nahata L, Bowman-Curci M, Quinn GP. new promising strategies in oncofertility. Expert Rev Qual Life Cancer Care. 2017;2(2):67–78. https://doi.org/10.1080/23809000.2017.1308808.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Krishnan M, Temel JS, Wright AA, Bernacki R, Selvaggi K, Balboni T. Predicting life expectancy in patients with advanced incurable cancer: a review. J Support Oncol. 2013;11(2):68–74. https://doi.org/10.12788/J.SUPONC.0004.

    Article  PubMed  Google Scholar 

  55. Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26(6):809–15. https://doi.org/10.1158/1055-9965.EPI-16-0889.

    Article  PubMed  PubMed Central  Google Scholar 

  56. McDermott D, Lebbé C, Hodi FS, et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 2014;40(9):1056–64. https://doi.org/10.1016/J.CTRV.2014.06.012.

    Article  PubMed  Google Scholar 

  57. Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(25):2363–76. https://doi.org/10.1056/NEJMOA2201445.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Schover LR. Patient attitudes toward fertility preservation. Pediatr Blood Cancer. 2009;53(2):281–4. https://doi.org/10.1002/PBC.22001.

    Article  PubMed  Google Scholar 

  59. Assi J, Santos J, Bonetti T, Serafini PC, Motta ELA, Chehin MB. Psychosocial benefits of fertility preservation for young cancer patients. J Assist Reprod Genet. 2018;35(4):601–6. https://doi.org/10.1007/S10815-018-1131-7.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Carter J, Rowland K, Chi D, et al. Gynecologic cancer treatment and the impact of cancer-related infertility. Gynecol Oncol. 2005;97(1):90–5. https://doi.org/10.1016/J.YGYNO.2004.12.019.

    Article  PubMed  Google Scholar 

  61. Ozkan S, Ogce F. Importance of social support for functional status in breast cancer patients. Asian Pac J Cancer Prev. 2008;9(4):601–4.

    PubMed  Google Scholar 

  62. Hurria A, Hurria A, Zuckerman E, et al. A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. J Am Geriatr Soc. 2006;54(7):1119–24. https://doi.org/10.1111/J.1532-5415.2006.00789.X.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. San Francisco School of Medicine, University of California San Francisco, San Francisco, CA, USA

    Mary Kathryn Abel

  2. Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA

    Mary Kathryn Abel, Ange Wang, Joseph M. Letourneau, Marcelle I. Cedars & Mitchell P. Rosen

  3. Deparment of Obstetrics and Gynecology, Brigham and Women’s Hospital, Massachusetts General Hospital, Harvard Medical School, 75 Francis Street, 3rd Floor, Boston, MA, 02115, USA

    Mary Kathryn Abel

  4. Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City, UT, USA

    Joseph M. Letourneau

  5. Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA

    Michelle E. Melisko

Authors
  1. Mary Kathryn Abel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ange Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph M. Letourneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michelle E. Melisko
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marcelle I. Cedars
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mitchell P. Rosen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.K.A., A.W., and M.P.R. wrote the main manuscript text and prepared the figures and tables. J.M.L, M.E.E., and M.I.C. provided commentary to the manuscript. All authors reviewed the manuscript.

Corresponding author

Correspondence to Mary Kathryn Abel.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abel, M.K., Wang, A., Letourneau, J.M. et al. Changing the Perspective on Fertility Preservation for Women with Metastatic or Advanced Stage Cancer. Curr Oncol Rep (2024). https://doi.org/10.1007/s11912-024-01530-9

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11912-024-01530-9

Keywords

Search

Navigation